Vilnius-Based Biomatter Raises $18M Series A Led by Astanor to Design Enzymes Not Found in Nature

The AI enzyme designer works with AstraZeneca, BASF and Sanofi, and is building a 2,000-square-meter lab in Lithuania.

Biomatter, a Vilnius, Lithuania-based company that uses AI to design enzymes, has raised an oversubscribed €16.2 million (about $18 million) Series A led by Astanor, The Recursive reported on November 12, 2026.


Who Invested


Astanor, a Brussels-based investor founded in 2017 that backs agrifood and bioeconomy companies, led the round. Previous backers UVC Partners, Inventure and Metaplanet also participated. Valuation was not disclosed.


The raise follows a €6.5 million seed round in August 2024, which UVC Partners and Inventure co-led with participation from Metaplanet and Practica Capital.


What Biomatter Does


Enzymes are the workhorses of industrial biology, used in everything from drug manufacturing to food processing. Most commercial enzymes are tweaked versions of ones found in nature. Biomatter, founded in 2018, takes the opposite approach: it starts from the chemical reaction a customer needs and designs a new enzyme to do it.


The company builds its own enzyme dataset and lab-tests every design before shipping. Laurynas Karpus is CEO and co-founder.


Traction


Biomatter says it has delivered more than 50 custom enzymes to over 25 enterprise customers in Europe, the U.S. and Japan, about half of them U.S.-based. Clients include AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi and Tereos.


Notable projects include improving Thermo Fisher's Invitrogen SuperScript V reverse transcriptase so it can ship at ambient temperature and be stored at room temperature for six months, and developing a methylase for mRNA vaccine manufacturing that works without SAM, a costly reagent. Revenue was not disclosed.


What the Money Is For


Most of the funding will go to a 2,000-square-meter design and testing facility in Vilnius, scheduled to open in 2027, which will bring build-and-test work in-house. Biomatter also plans to grow its commercial team, expand in the U.S. and invest in its computational platform and dataset. The company says the setup could cut enzyme development time from months or years to days.


Why It Matters


AI protein design has moved from academic breakthrough to commercial business, and enzyme makers are among the first to turn it into revenue. Biomatter's client list, spanning pharma, chemicals and food, shows how broad the demand is.


The lab is the strategic piece. Design models improve with experimental data, and owning the testing loop lets Biomatter generate that data faster than rivals that outsource it. For Central and Eastern Europe's startup scene, it is also a sign that deep-tech companies can scale serious infrastructure at home.


Source


The Recursive — "Lithuania's Biomatter Raises €16.2M Series A to Design Enzymes Not Found in Nature"

0 Comments